Expert commentary provided by Dr Phil Moore, Consultant Neuropsychologist/Clinical Psychologist, UK.
For half a century, the Glasgow Coma Scale has served as the universal shorthand for brain injury, but its rigid categories of “mild, moderate, and severe” are increasingly viewed as an oversimplification of a complex reality. A landmark international consensus published in The Lancet Neurology marks a turning point in this history, proposing the CBI-M model—a multidimensional framework designed to move neurocritical care into the era of precision medicine. By moving beyond a single, static triage score, this new approach offers a more granular foundation for long-term neurorehabilitation.
The CBI-M model is built upon four distinct pillars that replace traditional labels with a dynamic assessment. The Clinical pillar shifts the focus from a single admission snapshot to a 14-day tracking period of neurological data. This is bolstered by the Biomarker pillar, which introduces blood-based assays to detect microscopic cellular stress that standard CT scans often miss. Meanwhile, the Imaging pillar utilises advanced neuroimaging to map physical tissue damage, while the Modifiers pillar factors in the individual’s unique context—such as genomics, age, and pre-existing health—to forecast a more realistic recovery trajectory.
| Sign up to the ACNR email newsletter here |
For professionals in neurology and neurorehabilitation, this paradigm shift promises a move away from “one-size-fits-all” protocols toward deeply targeted interventions. By using objective data to set individualised goals, clinicians can better identify patients who might have been dismissed as “mild” cases but actually harbour significant structural risks. It represents a transition from simply describing an injury to understanding its specific mechanics within a specific person.
However, the path to implementing CBI-M within the UK’s National Health Service is fraught with structural hurdles. Most NHS labs do not yet have the infrastructure for routine TBI biomarker testing, and the high demand for MRI and CT scans remains a significant bottleneck. Furthermore, UK clinicians are bound by NICE guidelines that still mandate the use of the GCS. There is also a looming risk of a “postcode lottery,” where only major neuroscience centres have the resources to adopt these high-tech tools. Perhaps most critically for rehab specialists, the model’s focus on the first 14 days may miss the many UK patients who only seek help weeks after a seemingly minor injury.
Ultimately, while CBI-M offers a revolutionary roadmap for brain injury management, its arrival on UK wards will require substantial funding and a total overhaul of national regulatory standards.
| Sign up for our online community for neurology specialists |
Read more
